This filing relates to up to 300,000 shares of common stock that the selling securityholder may sell from time to time in one or more transactions in amounts, at prices and on terms that will be determined at the time of the offering. The selling securityholder will bear all commissions and discounts, if any, attributable to its sale of the shares of common stock.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SABS:
- SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
- SAB Biotherapeutics announces results from Phase 3 trial of SAB-185
- SAB Biotherapeutics Blasts Up on Flu Treatments
- SAB Biotherapeutics spikes 33% after FDA grants BTD to SAB-176
- SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
